Summary
Extensive animal data now exist to indicate potential benefit of sorbinil in the treatment of the major complications of diabetes mellitus. A clinical programme has been constructed to explore this therapeutic potential and encouraging evidence of drug effect has already been observed in patients with neuropathy and retinopathy. Two small preliminary studies in patients with painful neuropathy have shown that clinically significant reduction of pain was more frequently achieved with sorbinil than with placebo. A 6-month study of patients with retinopathy, using vitreous fluorophotometry as the criterion of retinal damage, showed significant (p=0.03) benefit for the sorbinil group compared with the placebo group. Drug evaluation in these areas is complex and difficult but it is anticipated that the accumulation of additional data will further substantiate the efficacy suggested by these early findings. The only clinically important adverse effect of sorbinil is the hypersensitivity reaction. This usually occurs during the initial weeks of therapy and is similar to that seen with phenytoin. The long term use of sorbinil is without significant adverse effects.
Similar content being viewed by others
Reference
Cunha-Vaz JG, Mota CC, Leite EC, et al. Effect of aldose reductase inhibitors on blood retinal barrier in early diabetic retinopathy. Diabetes 34 (Suppl. 1): 109A, 1985
Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy — a clinical and neurophysiological study. Journal of Neurology, Neurosurgery and Psychiatry 44: 991–1001, 1981
Jaspan J, Herold K, Bartleus C. Improvement in cardiac autonomic nerve dysfunction in diabetic patients with aldose reductase inhibitor therapy. Clinical Research 33: 433A, 1985
Zeimer RC, Blair NP, Cunha-Vaz JG. Vitreous fluorophotometry for clinical research. Archives of Ophthalmology 101: 1757–1761, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pitts, N.E., Gundersen, K., Mehta, D.J. et al. Aldose Reductase Inhibitors in Clinical Practice. Drugs 32 (Suppl 2), 30–35 (1986). https://doi.org/10.2165/00003495-198600322-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600322-00008